# HackBio-cancer-internshipImmune Checkpoints in Cancer: 

Immune Checkpoints in Cancer

Authors (@Slack): Rahma Mamdouh (rahma mam2000)

Introduction

Immune checkpoints are crucial regulators of immune responses, ensuring that the immune system does not overreact and cause damage to normal tissues. Key molecules, such as PD-1 and CTLA-4, play vital roles in inhibiting T-cell activity, thereby maintaining self-tolerance and preventing autoimmunity (Jiang & Geng, 2020). However, cancer cells can exploit these checkpoints to evade immune detection and continue proliferating unchecked. Blocking these immune checkpoints with inhibitors can reactivate the natural immune response, enabling it to target and eliminate cancer cells more effectively (Zhou et al., 2024).

Mechanisms of Immune Checkpoints

Immune checkpoints primarily function by modulating T-cell activity:

\- PD-1 (Programmed cell death protein 1): This receptor on T cells binds to its ligands, PD-L1 or PD-L2, on other cells, which inhibits T-cell activation and proliferation, thereby limiting the immune response (Jiang & Geng, 2020). 

\- CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4): This checkpoint molecule competes with the costimulatory receptor CD28 for binding to B7 molecules (CD80 and CD86) on antigen-presenting cells, which reduces T-cell activation (Zhou et al., 2024).

These mechanisms are essential for preventing hyperactive immune responses that could damage normal tissues but can be hijacked by cancer cells for immune evasion.

Immune Evasion by Cancer Cells

Cancer cells often exploit immune checkpoint pathways to avoid immune detection. For example, many tumors express high levels of PD-L1, which binds to PD-1 on T cells, leading to T-cell exhaustion and preventing effective immune responses against the cancer cells (Ribas & Wolchok, 2018). Similarly, tumors can upregulate molecules that activate CTLA-4, further inhibiting T-cell responses and allowing the cancer to evade immune surveillance and continue growing (Jiang & Geng, 2020).

Case Study: Checkpoint Inhibitors in Action

A case study presented by Ribas and Wolchok (2018) discusses a 54-year-old patient with advanced melanoma who was treated with pembrolizumab, an anti-PD-1 checkpoint inhibitor. This patient had previously undergone multiple lines of therapy, including chemotherapy and targeted therapy, with limited success. Following pembrolizumab treatment, the patient experienced significant tumor shrinkage within three months, as observed in imaging studies, and reported an improved quality of life with extended progression-free survival. This case illustrates the potential of pembrolizumab to achieve durable responses in patients who have exhausted other treatment options, underscoring the impact of immune checkpoint inhibitors in modern cancer therapy.

Conclusion

The development of immune checkpoint inhibitors represents a significant advancement in cancer treatment, offering new hope for patients. Continued research into immune checkpoints and their interactions will be crucial for enhancing existing treatments and discovering new strategies to combat cancer more effectively.

References:

1\. Zhou, Y., et al. (2024). From immune checkpoints to therapies: Understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer. \*Frontiers in Immunology, 15,\* 1340307. \[https\://doi.org/10.3389/fimmu.2024.1340307]\(https\://doi.org/10.3389/fimmu.2024.1340307)

2\. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. \*Science, 359\*(6382), 1350-1355. \[https\://doi.org/10.1126/science.aar4060]\(https\://doi.org/10.1126/science.aar4060)

3\. Jiang, Y., & Geng, X. (2020). Immune checkpoint inhibitors: Mechanism of action, efficacy, and safety. \*Journal of Hematology & Oncology, 13\*(1), 1-13. \[https\://doi.org/10.1186/s13045-020-00913-w]\(https\://doi.org/10.1186/s13045-020-00913-w)
